Tagline’s principal, Tara Rabin, joined RC Resolve (Real Chemistry’s healthcare advisory) for a discussion on what FDA leadership changes mean for pharmaceutical companies, patients, and the future of innovation. Six episodes of the “Resolve Radar” series have been released on Real Chemistry’s YouTube channel since the series launch in September, exploring regulatory uncertainty ahead of the midterm elections and beyond.
Tara brings her experience as a former FDA media relations and public affairs leader to the conversation alongside Kirsten Axelsen, senior policy advisor at DLA Piper. Leslie Isenegger, RC Resolve’s head of policy, public affairs and access, moderates the discussion.
Together, they examine how companies can distinguish consequential changes from policy speculation while navigating workforce pressures, reimbursement shifts, and global competition. Tara’s recurring advice: stay engaged, preserve dialogue with the agency, and keep decisions grounded in scientific evidence.
Episode 1: What’s Different About This Moment at FDA
Leslie opens by asking how recent leadership departures differ from previous FDA transitions and how career staff are maintaining continuity. The question has a timely backdrop: the Senate HELP Committee held FDA commissioner nominee Heidi Overton’s confirmation hearing on September 24.
Tara explains that organizational changes have left employees uncertain about where to find support and which priorities should guide them. That uncertainty “makes it harder to do the job that was already a hard job before,” she says.
She also emphasizes employees’ resilience as they assume unfamiliar responsibilities to sustain the public health mission. Stable leadership would provide clearer direction and greater confidence.
Episode 2: The 210-Day Clock: Don’t Chase Policy Chatter
Leslie asks how temporary leadership affects companies with applications under review, noting that FDA review output has remained consistent despite turnover. Tara distinguishes policy concepts from the established requirements reviewers must apply.
Scientific teams remain focused on “the facts, the science,” Tara says. Companies should follow policy discussions without assuming every proposal immediately changes their application’s prospects.
Tara identifies workforce capacity as a more concrete concern: departures, competing initiatives and additional responsibilities could strain teams working to meet existing review commitments.
Episode 3: PDUFA Reauthorization & the Global Competitiveness Stakes
Leslie, Tara and Kirsten turn to reauthorization of the Prescription Drug User Fee Act, or PDUFA. The episode highlights negotiations without a permanent FDA commissioner, alongside questions about artificial intelligence, clinical trial design, and U.S. competitiveness.
The discussion came as the PDUFA VIII public comment period reached its October 16 deadline. FDA plans to transmit recommendations to Congress by January 15, 2027, ahead of the current authorization’s September 30, 2027, expiration. Those milestones give added urgency to the episode’s focus on timely approvals, launches, and market availability. FDA timeline
Episode 4: Will FDA Leadership Changes Silence Patient Voices?
Leslie explores whether leadership changes could alter collaboration with sponsors or weaken patient participation. Tara explains that FDA’s encouragement of early engagement developed over several years, helping companies design trials and generate useful evidence.
Leadership may influence the boundaries of that engagement, but Tara expects patient perspectives to remain important. Clinical data cannot always fully convey unmet needs, lived experience, or the urgency facing patients.
“I don’t think that should go anywhere,” she says of patient participation.
Episode 5: What’s Shaping Biopharma Decisions?
Leslie asks how uncertainty is influencing investment, development, and filing decisions. Kirsten identifies reimbursement changes and international pricing risks as drivers of investment and launch choices, distinguishing those from regulatory filing decisions for already-developed assets.
Tara questions the durability of the Commissioner’s National Priority Voucher Program while expecting work on AI-assisted review to continue. FDA’s May announcement of Elsa 4.0, an upgrade to its internal AI tool for staff including scientific reviewers, provides a concrete example of that work entering agency operations.
Episode 6: Why Smart Biopharma Leaders Ignore the Noise
Leslie closes by placing leadership turnover alongside global competition, advances in science and AI. Tara urges companies to ask whether engaging in a particular policy debate will support their product’s development.
“There’s a lot of noise,” she says. “Ultimately, the data is the data.”
Kirsten reinforces the importance of unmet medical need, strong evidence, and reimbursement prospects, while recognizing that scientific advances are creating new opportunities. The closing message is practical: monitor change closely and keep the work centered on evidence and patient benefit.

